Waterfront Wealth Inc. Purchases 4,899 Shares of Edwards Lifesciences Co. (NYSE:EW)

Waterfront Wealth Inc. raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 44.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,865 shares of the medical research company’s stock after purchasing an additional 4,899 shares during the period. Waterfront Wealth Inc.’s holdings in Edwards Lifesciences were worth $1,174,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at approximately $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC lifted its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Finally, JFS Wealth Advisors LLC raised its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now directly owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $74.71 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $44.06 billion, a P/E ratio of 10.72, a PEG ratio of 4.89 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a 50-day moving average price of $72.86 and a 200 day moving average price of $69.86.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on EW. Robert W. Baird reduced their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.